Quercetin Actions on Lipid Profiles in Overweight and Obese Individuals: A Systematic Review and Meta-Analysis

source extracted confidence: high 2026-04-09
#dietary-supplements #humans #lipids #obesity #overweight

Quercetin Actions on Lipid Profiles in Overweight and Obese Individuals: A Systematic Review and Meta-Analysis

Guo et al., 2019 | Curr Pharm Des | Meta Analysis

Citation

Guo Wenfang, Gong Xue, Li Minhui. Quercetin Actions on Lipid Profiles in Overweight and Obese Individuals: A Systematic Review and Meta-Analysis. Curr Pharm Des. 2019;25(28):3087-3095. doi:10.2174/1381612825666190829153552

Abstract

BACKGROUND: The lipid profile is associated with metabolic diseases in overweight and obese individuals. Quercetin treatment is suggested to reduce the risk factors for obesity. OBJECTIVE: The aim of the literature meta-analysis was to determine the range of doses of quercetin administration on plasma lipid levels in overweight and obese human subjects. METHODS: Articles searched on EMBASE, PubMed, Cochrane Library, and Web of Science through March 20, 2019, were reviewed independently using predetermined selection criteria. The Cochrane collaboration's tool for assessing risk of bias was used to assess the quality of the included trials. Heterogeneity was measured using Cochran's Q test and the I-square (I2) statistic. Data were pooled using a random-effects model and the standardized mean difference (SMD) was considered for measuring the overall effect size. RESULTS: Of 176 articles reviewed, 9 randomized clinical trials were selected based on the inclusion criteria. The pooled results for the effect of quercetin administration on LDL-cholesterol (SMD: -002; 95% CI: -0.15-0.11), HDL-cholesterol (SMD: -0.06; 95% CI: -0.19-0.07), triglycerides (SMD: 0.05; 95% CI: -0.08-0.18), and total cholesterol (SMD: 0.04; 95% CI: -0.09-0.17) were not significantly different from the control group results. Quercetin administration at doses of ≥250 mg/day (SMD: -0.58 ; 95% CI: -0.94--0.22) and total dose ≥14,000 mg (SMD: -0.58 ; 95% CI: -0.94--0.22) significantly reduced LDL levels; however, HDL-cholesterol, triglycerides, and total cholesterol levels remained unchanged (p > 0.05). CONCLUSION: Quercetin administration does not affect plasma lipid levels in overweight and obese individuals. However, it significantly reduces LDL-cholesterol levels at doses of ≥250 mg/day and total dose ≥14000 mg.

Key Findings

Of 176 articles reviewed, 9 randomized clinical trials were selected based on the inclusion criteria. The pooled results for the effect of quercetin administration on LDL-cholesterol (SMD: -002; 95% CI: -0.15-0.11), HDL-cholesterol (SMD: -0.06; 95% CI: -0.19-0.07), triglycerides (SMD: 0.05; 95% CI: -0.08-0.18), and total cholesterol (SMD: 0.04; 95% CI: -0.09-0.17) were not significantly different from the control group results. Quercetin administration at doses of ≥250 mg/day (SMD: -0.58 ; 95% C

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Dietary Supplements
  • Humans
  • Lipids
  • Obesity
  • Overweight
  • Quercetin
  • Randomized Controlled Trials as Topic

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review
  • Vertical: quercetin

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09